Drug intelligence / Profile preview

WPC08

Development stage: Preclinical
Lead developer: Westlake Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

WPC08 is a preclinical-stage small molecule therapeutic being developed by Westlake Pharmaceuticals. It is designed to target epigenetic regulators and transcription factors, which are frequently dysregulated in various malignancies. By modulating these pathways, WPC08 aims to reprogram gene expression patterns in tumor cells to inhibit growth, induce apoptosis, or reverse treatment resistance. The program is currently in the drug discovery phase, focusing on the treatment of solid tumors and other cancers.

Targets

TF (Transferrin)

Beyond the preview

Go deeper on WPC08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPC08.

Explore the full profile